This IDC Health Insights report lays out the changing landscape for drug safety in the life science industry with a focus on the key processes, commercial tools, and available external service resources that are currently used to help organizations ensure and maintain full global regulatory compliance. As a core process in an industry undergoing transformation, drug safety is an area that is also being pressed for improved cost efficiency while concurrently facing an increasingly complex regulatory environment as companies expand globally.
"While global intolerance for drugs that are less than perfect in their safety profiles remains at an all-time high, life science companies still need to bring new drugs to market to survive. Faster and better use and exploitation of drug safety data across organizations will be key to working smarter and staying ahead as companies move into a new era in the life sciences," says Alan S. Louie, research director, IDC Health Insights.
Table of Contents
Table of Contents
IDC Health Insights Opinion
In This Study
Defining Drug Safety and Pharmacovigilance
Triggering Action in Drug Safety
The Best Practices
The Mature Drug Safety Commercial Application Ecosystem
The Expanding Drug Safety Services Ecosystem
Actions to Consider
Actions for Life Science Companies
Actions for Drug Safety Solution and Service Providers
Appendix: Common Drug Safety Abbreviations
Table: Selected Commercial Service Vendors by Category
Figure: Responding to a Drug Safety Event - A Flowchart View
Figure: Action and Timelines for a Drug Safety Event
Figure: Typical Process Workflow to an Adverse Drug Event
Figure: Selected Commercial Drug Safety Applications
Figure: Signal Detection Workflow and Commercial Solutions
Figure: Drug Safety Service Types and Task Examples
Best Practices: Drug Safety in the Life Science Industry - A Market Landscape published by IDC Health Insights in September 12, 2012. This report consists of Pages: 13 and the price starts from US $ 4500.